KDM5A and glioblastoma: Specifically, increased activity of KDM5A leading to a reduction in histone 3 lysine 4 trimethylation (H3K4me3) has been shown to mediate resistance to gefitinib and cisplatin in NSCLC cells and to temozolomide in glioblastoma cells.